TEST:

DCISionRT

P3, N=5270, Not yet recruiting, NRG Oncology

P=N/A, N=3000, Recruiting, PreludeDx | Trial completion date: Dec 2035 --> Dec 2036 | Trial primary completion date: Dec 2025 --> Dec 2026

P=N/A, N=1500, Active, not recruiting, PreludeDx | Recruiting --> Active, not recruiting | Trial completion date: May 2034 --> Dec 2035 | Trial primary completion date: May 2024 --> Jul 2025

7-gene biosignature test resulted in a 35% reduction in patients treated with adjuvant RT. Patients with higher decision scores were more likely to receive RT and to receive a greater RT dose.

The 7-gene predictive DCIS biosignature more reliably identified patients with low 10-year IBR rates and no significant RT benefit than traditional CP factors as well as those with elevated long term IBR rates that benefited from RT with substantial crossover for low and high risk clinicopathologic patients, respectively. The use of DCISionRT allows for more personalized and accurate risk stratification, preventing the under- and over-treatment of patients with suspected "low-risk" or "high-risk" DCIS based on current clinicopathologic factors.

The 7-gene biosignature with RRt identified a subset of HER2(3+) patients with greater IBR rates following BCS and RT beyond traditional clinical and pathologic features. Consideration of therapies to reduce these elevated IBR rates should be evaluated, including the incorporation of HER2-targeted therapy.

P=NA | N=NA | "Prelude Corporation...announced results of a cutting-edge study in Clinical Breast Cancer....The study evaluated HER2-positive patients treated with breast conserving surgery (BCS) plus radiation therapy (RT) to determine if the DCISionRT test could identify those patients with elevated residual risk remaining after treatment. The study showed that patients with the DCISionRT Residual Risk subtype had significantly higher in-breast recurrence (IBR) rates compared to those without the Residual Risk subtype (16.2% vs 1.6%, p=.01)....DCISionRT successfully identified two distinct groups of HER2(3+) DCIS patients treated with breast-conserving surgery (BCS) plus radiation therapy (RT) that could not be identified using traditional clinicopathologic factors."

P=N/A, N=3000, Recruiting, PreludeDx | Suspended --> Recruiting

In conclusion, Reddit is an invaluable community for breast cancer survivors and reflects the necessity of support groups. Our study demonstrates the importance of continuing support groups centered on providing a safe space to seek advice, vent, and find solidarity. It also stresses the demand for more education and workshops on coping, treatment decision-making, and understanding diagnoses and prognoses.

"Prelude Corporation...and Cancer Help Desk, have partnered to provide expert nurse navigation services for women diagnosed with ductal carcinoma in situ (DCIS) breast cancer. This alliance allows for direct engagement between newly diagnosed DCIS patients seeking assistance with clinical options and healthcare professionals trained in breast cancer patient navigation....This novel collaboration within the diagnostic laboratory testing space demonstrates a shared commitment to empowering patients with tools needed to inform their treatment decision-making and planning processes."

"Prelude Corporation...announced an important advancement in the field of breast cancer care with the publication of the PREDICT study in the Annals of Surgical Oncology (ASO)....Significant impact on treatment decisions: DCISionRT test results led to a change in pre-test to post-test RT recommendations for 38% of women, highlighting its clinical utility in optimizing treatment plans based on individual patient risk profiles. Net reduction in RT recommendations: Overall, the test contributed to a 20% net reduction in the number of women recommended for RT, potentially sparing many from unnecessary treatment and associated side effects."